Close Menu

NEW YORK (360Dx) – I-Med Pharma announced this week it has won a patent case in Canada against TearLab related to the I-Pen Osmolarity System.

In February 2016, TearLab filed suit in the Federal Court of Canada alleging that I-Med Pharma's I-Pen infringed on the Canadian patent for the TearLab Osmolarity System. TearLab sought a permanent injunction to keep the I-Pen off the market, as well as damages, according to I-Med Pharma.

This week, the court invalidated TearLab's patent claims and awarded costs to I-Med Pharma. TearLab said it plans to appeal the ruling.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.